Yunnan Botanee Bio-Technology Group Co.LTD (300957) Fundamentals 2026 — P/E 25.7x, Revenue Analysis | SniperIQ
Yunnan Botanee Bio-Technology Group Co.LTD (300957) is a CN-listed Consumer Defensive company in Household & Personal Products with a market capitalization of ¥14.1B, trading at ¥33.42 on the SHZ. This SniperIQ fundamentals page covers Yunnan Botanee Bio-Technology Group Co.LTD's valuation (P/E 25.7x, P/B 2.3x), profitability (net margin 9.8%), revenue (¥5.4B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Yunnan Botanee Bio-Technology Group Co.LTD's market cap?
Yunnan Botanee Bio-Technology Group Co.LTD (300957) has a market capitalization of approximately ¥14.1B, trading at ¥33.42 on the SHZ. Market cap moves with the live share price.
What is Yunnan Botanee Bio-Technology Group Co.LTD's P/E ratio?
Yunnan Botanee Bio-Technology Group Co.LTD's trailing twelve-month P/E ratio is 25.7x, with a price-to-book (P/B) of 2.3x. Valuation multiples are best compared with Consumer Defensive sector peers rather than read in isolation.
How profitable is Yunnan Botanee Bio-Technology Group Co.LTD?
Yunnan Botanee Bio-Technology Group Co.LTD runs a net profit margin of 9.8%, a gross margin of 74.2%, and an operating margin of 11.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Yunnan Botanee Bio-Technology Group Co.LTD generate?
Yunnan Botanee Bio-Technology Group Co.LTD reported revenue of ¥5.4B for fiscal year 2025, with net income of ¥506M and earnings per share (EPS) of 1.2. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Yunnan Botanee Bio-Technology Group Co.LTD pay a dividend?
Yunnan Botanee Bio-Technology Group Co.LTD offers a trailing dividend yield of about 1.9%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Yunnan Botanee Bio-Technology Group Co.LTD financially healthy?
Yunnan Botanee Bio-Technology Group Co.LTD carries a debt-to-equity ratio of 0.14x and a current ratio of 3.63x, with a market beta of 0.66. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Yunnan Botanee Bio-Technology Group Co.LTD a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Yunnan Botanee Bio-Technology Group Co.LTD (300957) the key facts are: market cap ¥14.1B, P/E 25.7x, revenue ¥5.4B, 52-week range 29.48-51.8. Weigh valuation, profitability, growth, and balance-sheet strength against Consumer Defensive peers and form your own view.
Track Yunnan Botanee Bio-Technology Group Co.LTD's full fundamentals live
Get Yunnan Botanee Bio-Technology Group Co.LTD's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.